Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -8.48% is 74% above its 5-year average of -32.31%, near the high end of its 5-year range (-59.75%–-1.42%).
48.40% above its 12-month average of -16.43%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -2.55%.
RETURN ON ASSETS (ROA)
-8.48%
RETURN ON ASSETS (ROA) AVG TTM
-16.43%
RETURN ON ASSETS (ROA) AVG 3Y
-20.20%
RETURN ON ASSETS (ROA) AVG 5Y
-32.31%
RETURN ON ASSETS (ROA) AVG 10Y
-32.38%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+48.40%
CURRENT VS 3Y AVG
+58.02%
CURRENT VS 5Y AVG
+73.75%
CURRENT VS 10Y AVG
+73.81%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
+68.48%
vs the sector median at left
Akebia Therapeutics, Inc.
Market Cap
$241.70M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
Market Cap
$244.56M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$246.96M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$247.23M
Return on Assets (ROA)
-49.04%
TTM Avg
-75.08%
3Y Avg
-74.95%
5Y Avg
-71.96%
Market Cap
$247.45M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$249.82M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$240.76M
Return on Assets (ROA)
-8.99%
TTM Avg
-7.90%
3Y Avg
-14.69%
5Y Avg
-13.78%
Market Cap
$242.46M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
-108.30%
Market Cap
$252.90M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $241.70M | -8.48% | -16.43% | -20.20% | -32.31% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.56M | N/A | -14.72% | -16.00% | -18.82% |
| Galectin Therapeutics Inc. (GALT)vs › | $246.96M | -187.80% | -213.40% | -188.65% | -151.14% |
| Invivyd, Inc. (IVVD)vs › | $247.23M | -49.04% | -75.08% | -74.95% | -71.96% |
| InflaRx N.V. (IFRX)vs › | $247.45M | -23.88% | -71.64% | -51.89% | -47.09% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.82M | -244.25% | -369.36% | -230.97% | -157.86% |
| High Tide Inc. (HITI)vs › | $240.76M | -8.99% | -7.90% | -14.69% | -13.78% |
| BioAge Labs Inc. (BIOA)vs › | $242.46M | -23.80% | -23.59% | -108.30% | -108.30% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $252.90M | -114.79% | -67.19% | -63.94% | -45.91% |
| Biodesix, Inc. (BDSX)vs › | $238.51M | -29.12% | -42.23% | -51.88% | -48.35% |
ROA
-8.5%
ROE
-118.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -1.42% |
| 2024-12-31 | -31.45% |
| 2023-12-31 | -21.48% |
| 2022-12-31 | -26.46% |
| 2021-12-31 | -53.28% |
| 2020-12-31 | -59.75% |
| 2019-12-31 | -36.26% |
| 2018-12-31 | -17.25% |
| 2017-12-31 | -21.12% |
| 2016-12-31 | -45.22% |
| 2015-12-31 | -42.48% |
| 2014-12-31 | -33.37% |
| 2013-12-31 | -37.98% |
| 2012-12-31 | -365.26% |
